Nvidia to launch downgraded AI chip for China after US export curbs – Reuters
Nvidia Corp (NASDAQ:NVDA, ETR:NVD) is preparing to launch a lower-spec version of its H20 artificial intelligence chip in China as early as July, according to a Reuters exclusive citing three sources.
The move follows fresh US export restrictions that effectively barred the original H20 from the Chinese market.
The revised chip, intended for major clients including Tencent and Alibaba, will feature significantly reduced memory and performance to comply with new US rules.
China remains a vital market for Nvidia, accounting for 13% of its annual revenue.
The H20 had previously been the most advanced AI chip the US permitted for Chinese sales. Chief executive Jensen Huang visited Beijing last month, underlining the market’s strategic importance to the company.
BioHarvest Sciences Inc. (NASDAQ:BHST), a developer of plant-based biologics, reported a 47% year-over-year jump in first-quarter revenue on Thursday, driven by strong demand for its flagship VINIA line of wellness products.
Revenue for the quarter ended March 31 rose to $7.9 million, topping internal forecasts, as gross margins expanded by 227 basis points to 58.5%.
The company said it expects second-quarter revenue of at least $8.5 million and forecast adjusted EBITDA breakeven in the second half of 2025.
CEO Ilan Sobel, citing growth in both consumer products and contract services, said:
Our first quarter of 2025 was highlighted by a step change in revenue growth and financial performance,
VINIA, a functional food product derived from red grape cells, surpassed 50,000 active subscribers as of February, with cumulative revenue since launch reaching $50 million. BioHarvest has expanded the line with new formats targeting younger consumers, including espresso and tea pods and chewable supplements.
The company is also advancing its Contract Development and Manufacturing Organization (CDMO) business, announcing progress on contracts with a Nasdaq-listed pharmaceutical company and Tate & Lyle. It said both projects validate its ability to develop plant-based, non-GMO biologic compounds for pharmaceutical, nutraceutical, and food companies.
BioHarvest said it has begun Stage 1 development work on a next-generation plant-based sweetener for Tate & Lyle and entered Stage 2 of its pharma CDMO project.
Sobel said the company is in active talks with other potential partners and expects to sign several new CDMO contracts by year-end.
The CEO added that the company’s AI-driven R&D capabilities would help scale future development efficiently.
READ the latest news shaping the Nvidia market at Newsvidia
Nvidia to launch downgraded AI chip for China after US export curbs – Reuters, source
